ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IFRX InflaRx NV

1.65
0.15 (10.00%)
Feb 27 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,003,277
Bid Price 1.51
Ask Price 1.75
News -
Day High 1.7388

Low
1.14

52 Week Range

High
7.2499

Day Low 1.48
Company Name Stock Ticker Symbol Market Type
InflaRx NV IFRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.15 10.00% 1.65 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.48 1.48 1.7388 1.65 1.50
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,520 1,003,277 $ 1.54 $ 1,549,563 - 1.14 - 7.2499
Last Trade Time Type Quantity Stock Price Currency
19:51:42 61 $ 1.65 USD

InflaRx NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
88.75M 54.12M - 20.16M -29.48M -0.54 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

InflaRx NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No IFRX Message Board. Create One! See More Posts on IFRX Message Board See More Message Board Posts

Historical IFRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.531.73881.401.50225,1080.127.84%
1 Month1.741.75991.401.55223,699-0.09-5.17%
3 Months1.402.111.301.62271,1320.2517.86%
6 Months3.844.301.141.73292,627-2.19-57.03%
1 Year2.097.24991.144.68800,923-0.44-21.05%
3 Years4.257.24990.77623.97674,274-2.60-61.18%
5 Years32.7053.100.77624.81707,519-31.05-94.95%

InflaRx NV Description

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Your Recent History

Delayed Upgrade Clock